Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses.

Publication Type:

Journal Article

Source:

PloS one, Volume 9, Issue 8, p.e103446 (2014)

Keywords:

2014, August 2014, Research Trials Office Core Facility - Biostatistics Service, Shared Resources, Specimen Processing Core Facility, Vaccine and Infectious Disease Division

Abstract:

Phambili, the Merck (MRK)-Adenovirus Type 5 (Ad5) HIV-1 gag/pol/nef subtype B vaccine study, conducted in South Africa, suspended enrollment and vaccination when companion study, Step, was found non-efficacious. Although the vaccine did not prevent HIV-1 infection or lower viral-load setpoint, immune responses recognized clades B and C HIV-1 subtypes. We investigated predictors of the vaccine-induced antigen-specific immune responses.